Shares of Vectura Group PLC (LON:VEC) have earned an average rating of “Buy” from the eight brokerages that are presently covering the stock. Eight investment analysts have rated the stock with a buy recommendation. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is GBX 222.25 ($2.75).

A number of equities analysts have recently commented on VEC shares. FinnCap reiterated a “buy” rating and set a GBX 225 ($2.78) price target on shares of Vectura Group PLC in a report on Tuesday, August 30th. Peel Hunt reiterated a “buy” rating and set a GBX 200 ($2.48) price target on shares of Vectura Group PLC in a report on Tuesday, August 30th. Numis Securities Ltd reiterated a “buy” rating and set a GBX 246 ($3.04) price target on shares of Vectura Group PLC in a report on Thursday, August 25th. Stifel Nicolaus restated a “buy” rating and issued a GBX 242 ($3.00) target price on shares of Vectura Group PLC in a report on Friday, July 29th. Finally, Citigroup Inc. restated a “buy” rating and issued a GBX 215 ($2.66) target price on shares of Vectura Group PLC in a report on Thursday, July 28th.

Shares of Vectura Group PLC (LON:VEC) traded down 1.92% during trading on Monday, hitting GBX 138.20. The stock had a trading volume of 1,560,637 shares. The firm has a 50-day moving average of GBX 138.66 and a 200 day moving average of GBX 155.13. Vectura Group PLC has a 1-year low of GBX 122.90 and a 1-year high of GBX 200.10. The company’s market capitalization is GBX 567.47 million.

In other news, insider Trevor Phillips sold 240,841 shares of the business’s stock in a transaction dated Tuesday, September 27th. The shares were sold at an average price of GBX 139 ($1.72), for a total transaction of £334,768.99 ($414,318.06). Also, insider Andrew Derodra bought 30,000 shares of the firm’s stock in a transaction dated Friday, September 30th. The shares were acquired at an average cost of GBX 138 ($1.71) per share, with a total value of £41,400 ($51,237.62).

About Vectura Group PLC

Vectura Group plc is a product development company. The Company focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases (airways diseases). The Company has eight products marketed by its partners and a portfolio of drugs in clinical development, a number of which have been licensed to pharmaceutical companies.

Receive News & Stock Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related stocks with our FREE daily email newsletter.